Sandoz Targets Double Sales by 2035
Swiss drugmaker Sandoz plans to more than double annual net sales by 2035 through a major expansion of its biosimilars portfolio. The company targets mid-single-digit sales growth and plans to increase its biosimilar drugs significantly.
Xurve View
Insights:
Xurve View
SANDOZ GROUP AG aims to more than double its annual net sales by 2035, targeting a portfolio centered heavily on biosimilar medicines. The Swiss drugmaker outlined the strategy during a capital markets briefing on Tuesday. The expansion relies on a wave of looming patent expiries for major branded drugs.
